Restorative oncodermatology: Diagnosis and management of dermatologic sequelae from cancer therapies - 07/08/21
, Brian P. Hibler, MD a, b, Cristian Navarrete-Dechent, MD c, Mario E. Lacouture, MD a, bAbstract |
The long-term survival of patients with cancer has risen dramatically during the last few decades. Despite this remarkable success, the same treatments that have enabled cure or remission often secondarily affect the skin, hair, and nails. Conditions including scarring, striae distensae, persistent alopecia, pigmentary changes, nail alterations, chronic radiation dermatitis, and radiation fibrosis have been associated with anxiety, depression, decreased quality of life, and impaired function. These dermatologic changes are cosmetically disfiguring, may limit activities, and are a visual reminder of past illness. Interventions toward improving these untoward sequelae and restoring the appearance and function of skin and appendages are critical for normalization and may contribute to improved quality of life in cancer survivors. Here, we outline dermatologic sequelae of cancer therapies with a review of medical and procedural treatment strategies to restore dermatologic health in the survivorship population.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : alopecia, cancer, cancer survivors, chemotherapy, dermal fillers, hyperpigmentation, hypopigmentation, lymphedema, neuromodulators, quality of life, radiation, reconstruction, scar, striae, surgery, telangiectasias
Abbreviations used : EGFR, HA, IPL, Nd:YAG, PA, PDL, QoL, RT
Plan
| Supported in part through National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. |
|
| Disclosure: Dr Rossi reports Allergan Inc: advisory board; American Society for Laser Medicine & Surgery: A. Ward Ford Memorial research grant; Biofrontera: consultant; Canfield Scientific: consultant; Cutera: consultant; DAR companies; Dynamed: consultant; Evolus: consultant; L’Oréal: travel; Lam Therapeutics: consultant; LeoPharma: research funding; Mavig: travel; Merz: consultant; Quantia MD: consultant; Regen: research funding; Regeneron; consultant; Skin Cancer Foundation: research grant; Skinfix: advisor; Society of Memorial Sloan Kettering Cancer Center: research funding. Dr Lacouture has held a consultant or advisory role with Amgen, AstraZeneca, Berg Pharma, Boehringer Ingelheim, Genentech, Janssen, Johnson & Johnson, Lutris, Novartis, Novocure, Oncoderm, Pierre Fabre, Pfizer, Deciphera, and QED Therapeutics. Drs Hibler and Navarrete-Dechent have no conflicts of interest to declare. |
|
| IRB approval status: This project utilized publicly data available (online) and did not require IRB approval. |
Vol 85 - N° 3
P. 693-707 - septembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
